logo
His Royal Highness The Duke of Edinburgh Participates in Canadian Education Events Supporting Youth Development and Experiential Learning Français

His Royal Highness The Duke of Edinburgh Participates in Canadian Education Events Supporting Youth Development and Experiential Learning Français

Cision Canada10-07-2025
CHARLOTTETOWN, PE and TORONTO, July 10, 2025 /CNW/ - As part of his broader visit to Canada, His Royal Highness The Duke of Edinburgh, participated in two key education events hosted by Award Canada, underscoring his ongoing commitment to youth development and experiential learning.
In his role as Chairman of The Duke of Edinburgh's International Award Foundation, The Duke joined education leaders, and community partners at the Atlantic Canada Education Forum in Charlottetown and the Ontario Education Leadership Gathering in Toronto. The Honourable Edith Dumont, Lieutenant Governor of Ontario, also attended the Ontario event, lending her distinguished support to the province's commitment to youth development. Their presence brought global and provincial visibility to a growing national effort to embed the Award into public education systems through a strategic Co-curricular Approach.
"These partnerships speak to the core of our strategy," said Amy Langhorne, Chair of Award Canada. "Across the country, education leaders are embracing a shared vision of student success—one that goes beyond academics to include purpose, employability, and well-being. Their commitment is bringing the Award into schools not as something extra, but as something essential."
A Strategic Shift in Canadian Education
The Co-curricular Approach represents a deliberate evolution in how the Award is delivered in Canada—moving from extracurricular, independently licensed models to a scalable, inclusive framework integrated within public education. This shift aligns with provincial goals around student well-being, career readiness, equity, and whole-student development.
At both events, education leaders shared how the Award is being used to:
Support Specialist High Skills Major (SHSM) programs and skilled trades pathways
Enhance student reflection, goal-setting, and resilience
Expand access to underserved, multilingual, and equity-deserving communities
Build bridges between secondary and postsecondary education
Prince Edward Island – Atlantic Canada Education Forum:
In Prince Edward Island, the Atlantic Canada Education Forum brought together senior officials and education leaders from across the region for a solutions-focused dialogue on advancing youth development through public education. Framed as a conversation at the intersection of vision and action, the forum explored how the Award's Co-curricular Approach can help redefine student success—focusing not just on what students know, but who they are becoming. Participants emphasized the importance of aligning the Award with regional priorities such as equity, student well-being, and life readiness.
Key highlights included:
A roundtable on "Unlocking Access and Advancing Equity," emphasizing the Award's role in supporting underserved and multilingual learners.
A showcase of Newfoundland and Labrador's province-wide pilot, including use in Careers education, functional curriculum, and Deaf and Hard of Hearing portfolios.
Strong cross-provincial engagement around embedding the Award within existing system frameworks—not as an add-on, but as a flexible structure to support whole-student development.
Presentation of an Education Operating Partnership certificate to the Government of Newfoundland and Labrador, recognizing its leadership and commitment to the co-curricular approach.
Ontario – Education Leadership Gathering:
In Ontario, the Education Leadership Gathering underscored the province's growing momentum in transforming how student success is defined and supported. The event brought together key education leaders to reflect on the Award's alignment with Ontario's education priorities, including mental health, equity, and career readiness. The tone was one of collaboration and purpose, as school board leaders shared both current outcomes and future aspirations for integrating the Award into public education.
Key highlights included:
Greater Essex County District School Board reaffirmed its leadership as the first provincial Education Operating Partner.
Peel District School Board is exploring a partnership focused on multilingual learners and equity.
Fanshawe College was welcomed as the first post-secondary Education Operating Partner, launching the Award through its Women in Skilled Trades program.
Halton Catholic District School Board is exploring a pilot launch for this fall, with discussions currently underway.
"As a high school student, I gravitated toward experiences outside the classroom—they helped me find myself, build resilience, and gave me the confidence to lead on the global stage," said Andrea Chakma, Canadian Gold Award Holder and International Youth Representative for the Americas Region. "That's why I'm excited about the co-curricular approach—it brings the Award into schools, making experiential learning a right, not a privilege."
A National Vision, Backed by Results
According to Award Canada's 2024 Impact Report, over 11,000 young people across Canada participated in the Award last year, supported by more than 1,400 adult mentors. With a goal to reach 12,000+ participants in 2025 and expand through new Educational Operating Partnerships, the momentum is clear.
"It's incredibly energizing to imagine the thousands of young people who will benefit as provincial education authorities and school boards embrace the Award," said Dr. Mark Little, CEO of Award Canada. "In today's world, it's increasingly difficult for youth to break through barriers to employment or post-secondary opportunities. By adopting the Award as a tool to support the 'whole student,' school boards are affirming the importance of holistic education—one that builds life skills, resilience, and supports both physical and mental well-being"
About Award Canada:
The Duke of Edinburgh's International Award – Canada (Award Canada) is the national operator of The Duke of Edinburgh's International Award, a global framework that supports youth development leading to international accreditation. With guidance from adult mentors, each young person is encouraged to challenge themselves, identify and leverage their interests, abilities, and ambitions, then set personal goals in four areas: skill, physical and mental health, community involvement, and teamwork. The Award provides fun and motivation by empowering student voice and engagement, enabling them to undertake experiences that build character, personal belief, and lifelong skills.
We exist to equip every young person in Canada, regardless of background or life circumstance, with the necessary skills and experience to succeed in life. Whoever they are, wherever they come from, and whatever they define as success, the Award helps young people develop essential skills that only come through experience. We have been supporting youth in Canada for over 60 years, transforming the lives of over 500,000 young people from all backgrounds, cultures, and abilities. Globally, the Award operates in over 130 countries, engaging 1.3 million participants.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canada's new drug pricing guidelines are industry-friendly
Canada's new drug pricing guidelines are industry-friendly

Canada News.Net

time36 minutes ago

  • Canada News.Net

Canada's new drug pricing guidelines are industry-friendly

Share article Print article Drug pricing in Canada just got more industry-friendly. Canadian drug prices are already the fourth highest in the industrialized world. Now, with the release of new guidelines for the staff at the Patented Medicine Prices Review Board (PMPRB) at the end of June, the situation is poised to potentially get even worse. The review board is the federal agency that was set up 1987 to ensure that the prices for patented drugs are not "excessive." Up until now, one of the criteria the PMPRB used in making the decision about what was an excessive price was to compare the proposed Canadian price for a new drug with the median price in 11 other countries. The median is the 50 per cent mark; in other words, the price in half of the other countries was below what's proposed for Canada, and the price in the other half was above the proposed Canadian price. Under the new guidelines, set to take effect on Jan. 1, 2026, the Canadian price can be up to the highest in those other 11 countries. Right now, the median price in the 11 countries Canada is compared to is 15 per cent below the price of patented drugs in Canada. The highest international price, which will be the new standard, is 21 per cent above the median Canadian price, meaning Canadian prices for new drugs will be significantly higher than they otherwise would have been. Sometimes a drug is not available in any of the 11 other countries when it comes onto the Canadian market. In that case, the company can price the drug at whatever level it wants and keep it at that price until it comes up for its annual price review. The executive director of the PMPRB told the Globe and Mail that this would incentivize drugmakers to bring their products to the Canadian market first. Incentivizing drug companies may be a reasonable idea, but that's not part of the mandate of the PMPRB. As laid out in Section 83 of the Patent Act, its mandate is to ensure drug prices aren't excessive. In the past, one of the factors that the PMPRB took into account in determining if prices were excessive was the additional therapeutic value of a new drug compared to what was already on the market. The lower the value, the lower the price. In this regard, the PMPRB was advised by its Human Drug Advisory Panel, an independent group of experts. The ranking of new drugs against existing ones was also of significant value to Canadian clinicians. It helped them to decide on the best treatment option for their patients and countered the hype about new drugs that came from the manufacturers. Since the new guidelines have abandoned looking at therapeutic improvement of new drugs, that leaves only one remaining Canadian source for that type of information, the Therapeutics Letter, a bimonthly publication targeting identified problematic therapeutic issues in a brief, simple and practical manner. Complaints about prices can be made by federal, provincial and territorial health ministers and by senior officials who are authorized to represent Canadian publicly funded drug programs. " Other parties who have concerns about the list prices ... are encouraged to raise their concerns with their relevant Minister(s) of Health or Canadian publicly-funded drug program (sic)." This advice is cold comfort for people working low-wage jobs who aren't covered by provincial and territorial drug plans and don't have any access to their health minister. If there is an in-depth review of a new drug's pricing - a preparatory step to determine whether there should be a formal hearing to investigate if the price is excessive - it is only the manufacturer that is allowed to submit information to the PMPRB. Clinicians who prescribe the drug, patients who take the drug, and organizations and individuals that pay for the drug do not have that same right. Donald Trump's on-again, off-again tariffs are already threatening to drive up drug prices and make prescription drugs inaccessible to many Canadians. Higher drug prices will also almost certainly affect Canada's already limited pharmacare program. Higher prices for new drugs will make an expanded pharmacare plan more expensive and less appealing to the federal government. The new PMPRB guidelines help ensure higher drug prices and no pharmacare expansion.

Canada's new drug pricing guidelines are industry friendly
Canada's new drug pricing guidelines are industry friendly

Canada News.Net

time37 minutes ago

  • Canada News.Net

Canada's new drug pricing guidelines are industry friendly

Share article Print article Drug pricing in Canada just got more industry-friendly. Canadian drug prices are already the fourth highest in the industrialized world. Now, with the release of new guidelines for the staff at the Patented Medicine Prices Review Board (PMPRB) at the end of June, the situation is poised to potentially get even worse. The review board is the federal agency that was set up 1987 to ensure that the prices for patented drugs are not "excessive." Up until now, one of the criteria the PMPRB used in making the decision about what was an excessive price was to compare the proposed Canadian price for a new drug with the median price in 11 other countries. The median is the 50 per cent mark; in other words, the price in half of the other countries was below what's proposed for Canada, and the price in the other half was above the proposed Canadian price. Under the new guidelines, set to take effect on Jan. 1, 2026, the Canadian price can be up to the highest in those other 11 countries. Right now, the median price in the 11 countries Canada is compared to is 15 per cent below the price of patented drugs in Canada. The highest international price, which will be the new standard, is 21 per cent above the median Canadian price, meaning Canadian prices for new drugs will be significantly higher than they otherwise would have been. Sometimes a drug is not available in any of the 11 other countries when it comes onto the Canadian market. In that case, the company can price the drug at whatever level it wants and keep it at that price until it comes up for its annual price review. The executive director of the PMPRB told the Globe and Mail that this would incentivize drugmakers to bring their products to the Canadian market first. Incentivizing drug companies may be a reasonable idea, but that's not part of the mandate of the PMPRB. As laid out in Section 83 of the Patent Act, its mandate is to ensure drug prices aren't excessive. In the past, one of the factors that the PMPRB took into account in determining if prices were excessive was the additional therapeutic value of a new drug compared to what was already on the market. The lower the value, the lower the price. In this regard, the PMPRB was advised by its Human Drug Advisory Panel, an independent group of experts. The ranking of new drugs against existing ones was also of significant value to Canadian clinicians. It helped them to decide on the best treatment option for their patients and countered the hype about new drugs that came from the manufacturers. Since the new guidelines have abandoned looking at therapeutic improvement of new drugs, that leaves only one remaining Canadian source for that type of information, the Therapeutics Letter, a bimonthly publication targeting identified problematic therapeutic issues in a brief, simple and practical manner. Complaints about prices can be made by federal, provincial and territorial health ministers and by senior officials who are authorized to represent Canadian publicly funded drug programs. " Other parties who have concerns about the list prices ... are encouraged to raise their concerns with their relevant Minister(s) of Health or Canadian publicly-funded drug program (sic)." This advice is cold comfort for people working low-wage jobs who aren't covered by provincial and territorial drug plans and don't have any access to their health minister. If there is an in-depth review of a new drug's pricing - a preparatory step to determine whether there should be a formal hearing to investigate if the price is excessive - it is only the manufacturer that is allowed to submit information to the PMPRB. Clinicians who prescribe the drug, patients who take the drug, and organizations and individuals that pay for the drug do not have that same right. Donald Trump's on-again, off-again tariffs are already threatening to drive up drug prices and make prescription drugs inaccessible to many Canadians. Higher drug prices will also almost certainly affect Canada's already limited pharmacare program. Higher prices for new drugs will make an expanded pharmacare plan more expensive and less appealing to the federal government. The new PMPRB guidelines help ensure higher drug prices and no pharmacare expansion.

Kiwetinohk announces upcoming second quarter 2025 earnings release
Kiwetinohk announces upcoming second quarter 2025 earnings release

Globe and Mail

timean hour ago

  • Globe and Mail

Kiwetinohk announces upcoming second quarter 2025 earnings release

CALGARY, AB , July 24, 2025 /CNW/ - Kiwetinohk Energy Corp. (TSX: KEC) management will host a conference call on July 31, 2025 , at 8 AM MT ( 10 AM ET ) to discuss second quarter 2025 results and answer questions. Participants can listen to the conference call by dialing 1-888-510-2154 ( North America toll free) or 437-900-0527 ( Toronto and area). A replay of the call will be available until August 7, 2025 , at 1-888-660-6345 ( North America toll free) or 646-517-4150 ( Toronto and area) by using the code 92805. About Kiwetinohk Kiwetinohk produces natural gas, natural gas liquids, oil and condensate from profitable early to mid-life liquids-rich natural gas properties focused in the Montney and Duvernay formations in Alberta, Canada . Kiwetinohk's common shares trade on the Toronto Stock Exchange under the symbol KEC. Additional details are available on Kiwetinohk's website at and SEDAR+ at For more information on Kiwetinohk, please contact: Investor Relations Investor Relations email: IR@ Investor Relations phone: (587) 392-4395 Pat Carlson , Chief Executive Officer Jakub Brogowski, Chief Financial Officer

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store